The term “special population” exists to protect certain vulnerable patient groups that require additional consideration as it pertains to clinical research, including women, pediatrics, and the elderly.
Artificial intelligence (AI) is the industry’s latest buzzword and is being touted as the solution to myriad problems. So where will it have the biggest impact across the drug development continuum? From identifying repurposable drugs, to mining data...
Be a catalyst for change at the 2019 Bridging Collaborative where thought leaders come together to advance clinical research and health care. Establish solutions to increase knowledge-sharing from clinical research.
The DIA 2019 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance...
SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions.
Drug counterfeiting: a pharmaceutical industry problemCounterfeiters rely on two things: poorly secured pharmaceutical supply chains; and the fact people want to pay less for less for drugs.Most fake erectile dysfunction drugs seized in Europe contain...
This event will examine the drug excipients market, from the historical events that have defined the sector to the debates going on at the moment to predictions about the demands that will drive it in the future.How did the DEG tragedies of the last century...
It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.But,...
How healthy is demand for bioavailability enhancement services? Is the growth of the generics sector driving the market or do innovative pharma firms determine the type of solubility solutions that are available.When biopharmaceutical are injected they...
Tablets have been around for almost 200 years. In this presentation we trace the history of their development, from the accidental invention of the sustained release pill through to the latest breakthroughs in bioavailability enhancement, this talk will...
How do you take a successful bioavailability solution from the laboratory to the pilot plant and on to commercial-scale production? What are the potential pitfalls and considerations involved in successfully scaling-up the production of a poorly soluble...
Creating an Amorphous Solid Dispersion (ASD) is an increasingly popular way of improving Active Pharmaceutical Ingredient (API) solubility. But while the approach can be successful, the big problem is demonstrating ASD stability, preventing ingredients...
This webinar will give you a better understanding of how the end of one-size-fits all medicine, and current oncology drug developments in diagnosis and biomarkers positively impact clinical trials. It will also address key oncology drug development barriers...
Clinical trials in the Asia Pacific are increasing exponentially. Numerous sponsors and CROs have accessed this region in recent years to take advantage of high performing, cost effective sites. To many sponsors though, Asia Pacific appears an impenetrable...
